Biogen slides as investors reassess Alzheimer’s data and earnings overhang

Biogen Inc. (BIIB) is down 8.0% today. Here is some analysis on what might have caused this price movement. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/07/14/3326960/0/en/biogen-presents-phase-2-celia-data-at-aaic-demonstrating-meaningful-clinical-outcomes-and-robust-tau-reduction-with-diranersen-in-early-alzheimer-s-disease.html?utm_source=openai))

Analysis: The selloff appears tied mainly to investor reassessment of Biogen’s Alzheimer’s pipeline after detailed Phase 2 CELIA data for diranersen showed encouraging biomarker and cognitive signals but still no clear dose-response pattern, which was the study’s primary endpoint. This could also be because traders are weighing those mixed clinical takeaways against a recently disclosed earnings hit from acquired in-process R&D, upfront, and milestone expenses. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/07/14/3326960/0/en/biogen-presents-phase-2-celia-data-at-aaic-demonstrating-meaningful-clinical-outcomes-and-robust-tau-reduction-with-diranersen-in-early-alzheimer-s-disease.html?utm_source=openai))

Details:

Biogen presented additional CELIA data on July 14, 2026 and said diranersen showed slowing of decline on several cognitive measures plus reductions in tau biomarkers. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/07/14/3326960/0/en/biogen-presents-phase-2-celia-data-at-aaic-demonstrating-meaningful-clinical-outcomes-and-robust-tau-reduction-with-diranersen-in-early-alzheimer-s-disease.html))

Even so, Biogen had already disclosed in May that CELIA did not meet its primary endpoint assessing dose response, and the detailed AAIC update noted that higher doses were not associated with greater slowing of decline. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/topline-results-phase-2-celia-study-diranersen-biib080-first?utm_source=openai))

That kind of mixed readout can pressure biotech shares when expectations have risen ahead of a conference presentation, especially after a favorable analyst upgrade helped lift the stock the prior session. ([au.finance.yahoo.com](https://au.finance.yahoo.com/news/truist-upgrades-biogen-buy-alzheimer-133408177.html?utm_source=openai))

Separately, a July 1 filing said second-quarter 2026 results should include about $164 million of expense, with a per-share impact of about $0.95, while third-quarter expense could be materially higher if additional milestones are triggered. ([sec.gov](https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/biib-20260701.htm))

Sources:

Biogen, SEC, Yahoo Finance ([globenewswire.com](https://www.globenewswire.com/news-release/2026/07/14/3326960/0/en/biogen-presents-phase-2-celia-data-at-aaic-demonstrating-meaningful-clinical-outcomes-and-robust-tau-reduction-with-diranersen-in-early-alzheimer-s-disease.html))

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BIIB Insider Trading Activity

$BIIB insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:

PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive BIIB Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BIIB Hedge Fund Activity

We have seen 463 institutional investors add shares of $BIIB stock to their portfolio, and 353 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 3,381,678 shares (+35.9%) to their portfolio in Q1 2026, for an estimated $619,963,027
POINT72 ASSET MANAGEMENT, L.P. removed 2,003,575 shares (-71.2%) from their portfolio in Q1 2026, for an estimated $367,315,404
BLACKROCK, INC. added 1,163,231 shares (+7.9%) to their portfolio in Q1 2026, for an estimated $213,255,139
MILLENNIUM MANAGEMENT LLC removed 1,031,622 shares (-91.7%) from their portfolio in Q1 2026, for an estimated $189,127,261
BARCLAYS PLC removed 753,533 shares (-57.7%) from their portfolio in Q1 2026, for an estimated $138,145,204
WELLINGTON MANAGEMENT GROUP LLP removed 589,628 shares (-16.6%) from their portfolio in Q1 2026, for an estimated $108,096,501
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 521,385 shares (-78.8%) from their portfolio in Q1 2026, for an estimated $95,585,512

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BIIB Congressional Stock Trading

Members of Congress have traded $BIIB stock 6 times in the past 6 months. Of those trades, 5 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/05, 01/30 and 0 sales.
REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 4 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 1 sale worth up to $50,000 on 06/02.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BIIB Analyst Ratings

Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 06/29/2026
Evercore ISI Group issued a "Outperform" rating on 05/15/2026
Guggenheim issued a "Buy" rating on 04/30/2026
Oppenheimer issued a "Outperform" rating on 01/30/2026

To track analyst ratings and price targets for $BIIB, check out Quiver Quantitative's $BIIB forecast page.

$BIIB Price Targets

Multiple analysts have issued price targets for $BIIB recently. We have seen 19 analysts offer price targets for $BIIB in the last 6 months, with a median target of $225.0.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $222.0 on 07/08/2026
Brian Abrahams from RBC Capital set a target price of $242.0 on 07/07/2026
Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
Yatin Suneja from Guggenheim set a target price of $260.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.